Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Non-Current Debt (2017 - 2024)

Organogenesis Holdings (ORGO) has 8 years of Non-Current Debt data on record, last reported at $56.2 million in Q3 2024.

  • For Q3 2024, Non-Current Debt fell 9.6% year-over-year to $56.2 million; the TTM value through Sep 2024 reached $56.2 million, down 9.6%, while the annual FY2023 figure was $60.7 million, 8.28% down from the prior year.
  • Non-Current Debt reached $56.2 million in Q3 2024 per ORGO's latest filing, down from $57.7 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $71.7 million in Q3 2021 and bottomed at $10.0 million in Q1 2020.
  • Average Non-Current Debt over 5 years is $51.6 million, with a median of $60.7 million recorded in 2023.
  • The widest YoY moves for Non-Current Debt: up 607.69% in 2021, down 81.12% in 2021.
  • A 5-year view of Non-Current Debt shows it stood at $10.0 million in 2020, then soared by 607.69% to $70.8 million in 2021, then fell by 6.41% to $66.2 million in 2022, then dropped by 8.28% to $60.7 million in 2023, then dropped by 7.56% to $56.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $56.2 million in Q3 2024, $57.7 million in Q2 2024, and $59.4 million in Q1 2024.